Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.51
-0.01 (-0.18%)
Dec 3, 2024, 1:59 PM EST - Market open
Verastem Employees
Verastem had 73 employees as of December 31, 2023. The number of employees increased by 16 or 28.07% compared to the previous year.
Employees
73
Change (1Y)
16
Growth (1Y)
28.07%
Revenue / Employee
$136,986
Profits / Employee
-$1,280,192
Market Cap
245.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aurora Cannabis | 1,073 |
Inogen | 834 |
MacroGenics | 339 |
Alector | 244 |
biote | 194 |
Solid Biosciences | 88 |
Acrivon Therapeutics | 61 |
Sera Prognostics | 57 |
VSTM News
- 6 days ago - Verastem: Preparing For Upcoming Catalysts - Seeking Alpha
- 7 days ago - Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 26 days ago - Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - Business Wire
- 4 weeks ago - Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - Business Wire
- 4 weeks ago - Verastem Oncology to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - Business Wire
- 7 weeks ago - Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - Business Wire
- 2 months ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire